



Press Release

June 15, 2020 at 8:00 a.m. Finnish time

Nanoform Finland Plc appoints Peter Hänninen as General Counsel

Nanoform Finland Plc (“**Nanoform**”) today announced the appointment of Peter Hänninen as General Counsel, effective as of September 1, 2020. In this role, he leads Nanoform’s legal operations, including in-house and external legal affairs, intellectual property rights, corporate and commercial matters, compliance and governance. This is a new position within Nanoform and the General Counsel will report to the CEO.

Peter Hänninen joins Nanoform from Borenium Attorneys where his practice focused on a broad range of corporate and commercial matters for technology companies, particularly in the life sciences and healthtech sectors. He holds a Master of Law degree from the University of Helsinki.

“Peter has been a key asset for us in building Nanoform into the company it is today. We are thrilled to welcome Peter to Nanoform in this new role, and we look forward to continue working together to further our vision of doubling the number of drugs that reach the market each year,” stated Edward Haeggström, Nanoform CEO and founder.

Further enquiries:

Edward Hæggström, CEO
edward.haeggstrom@nanoform.com

Henri von Haartman, Director of Investor Relations
hvh@nanoform.com
+46 7686 650 11

Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806

Nanoform in brief

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce attrition in clinical trials and enhance their molecules’ formulation performance through its nanoforming services. The Company’s patented and scalable Controlled Expansion of Supercritical Solutions (CESS®) technology produces nanoformed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Nanoform’s unique technology provides novel opportunities in many value-enhancing drug delivery applications. www.nanoform.com